摘要
目的:研究120例乳腺癌中ER、PR、P53、HER-2及TOPⅡ表达和临床意义。方法:应用免疫组化SP法测得ER、PR、P53、HER-2及TOPⅡ在120例乳腺癌中表达情况。结果:ER、PR、P53、HER-2及TOPⅡ的表达分别是:48(40.00%)、50(42.67%)、71(59.17%)、67(55.83%)、69(57.50%)。P53的表达与HER-2呈正相关,P53、HER-2的表达与ER,PR呈负相关(P<0.05);ER、PR的表达与肿瘤临床分期及淋巴结转移呈负相关。P53、HER-2的表达与肿瘤临床分期及淋巴结转移呈正相关(P<0.05)。结论:TOPⅡ、HER-2是判断乳腺癌预后的参考指标,ER、PR、P53、HER-2及TOPⅡ联合检测对乳腺癌治疗方案及预后判断有重要临床意义。
Objective：To study the expression of the estrogen receptor （ER） , progesterone receptor （PR） , p53protein, HER-2, and topoisomerase Ⅱ （TOP Ⅱ ） in 120 cases with breast cancer and its clinical significance. Methods： The specimens obtained from 120 cases of breast cancer were stained by immnno-histochemical methods for ER, PR, P53, HER-2, and TOPⅡ. Results ： The rate of ER, PR,P53 ,HER-2, and TOPⅡ expression were 48 （40. 00% ） ,50 There was a positive correlation between the expression of P53 and （42.67%）,71 （59. 17%）,67 （55.83%）,and 69 （57.50%）. HER-2 ;There was a negative correlation between the expression of P53, HER-2, and ER, PRⅡ（P 〈 0. 05 ） , clinical stages of the tumor and lymph node metastasis had a negative correlation with ER, PR, and P53. HER-2 had a positive correlation with clinical stages of the tumor and lymph node metastasis （ P 〈 0. 05 ）. Conclusion ： HER- 2 and TOPⅡ are important prognosis factors for breast cancer patients. Combined detection of ER, PR, P53, HER-2, and TOP II may play a certain role in the clinical treatment and prognostic judgement of breast cancer patients.
出处
《川北医学院学报》
CAS
2012年第3期213-215,共3页
Journal of North Sichuan Medical College
